Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives $15.67 Consensus Price Target from Brokerages

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) has earned a consensus recommendation of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $15.6667.

Several equities analysts have issued reports on BWAY shares. Weiss Ratings upgraded Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research note on Friday, April 24th. Zacks Research upgraded shares of Brainsway from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Wall Street Zen raised shares of Brainsway from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Brainsway in a research report on Friday, July 17th. Finally, BTIG Research assumed coverage on shares of Brainsway in a research note on Monday. They set a “buy” rating and a $18.00 price objective for the company.

Institutional Trading of Brainsway

A number of institutional investors have recently made changes to their positions in the business. Masters Capital Management LLC increased its position in Brainsway by 65.0% during the 1st quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company’s stock valued at $21,928,000 after buying an additional 650,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Brainsway by 87.2% in the first quarter. Renaissance Technologies LLC now owns 518,420 shares of the company’s stock worth $6,890,000 after acquiring an additional 241,560 shares in the last quarter. Y.D. More Investments Ltd boosted its holdings in Brainsway by 136.6% in the first quarter. Y.D. More Investments Ltd now owns 272,004 shares of the company’s stock worth $3,615,000 after acquiring an additional 157,042 shares in the last quarter. Sei Investments Co. grew its stake in shares of Brainsway by 262.5% during the first quarter. Sei Investments Co. now owns 226,378 shares of the company’s stock worth $3,009,000 after acquiring an additional 163,925 shares during the last quarter. Finally, ARK Investment Management LLC purchased a new stake in shares of Brainsway during the fourth quarter worth about $2,422,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Brainsway Trading Up 2.5%

Shares of NASDAQ BWAY opened at $16.56 on Monday. Brainsway has a 12-month low of $5.68 and a 12-month high of $17.35. The stock’s fifty day simple moving average is $15.00 and its two-hundred day simple moving average is $13.89. The stock has a market capitalization of $664.55 million, a PE ratio of 47.32 and a beta of 1.22.

Brainsway (NASDAQ:BWAY) last released its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.05 by $0.07. Brainsway had a return on equity of 12.28% and a net margin of 15.68%.The firm had revenue of $15.53 million during the quarter, compared to analyst estimates of $14.63 million. On average, equities analysts predict that Brainsway will post 0.33 earnings per share for the current fiscal year.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.